Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 2 Interventional Results available

A Study of Sublingual Immunotherapy in Peanut-allergic Children

NCT00597727
View directory record Official record
Conditions
Food Hypersensitivity
Interventions
Peanut SLIT, Placebo SLIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 14, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

NCT06974773
View directory record Official record
Conditions
Endometriosis
Interventions
NettleEndo, Sham NettleEndo Device
Device
Lead sponsor
Samphire Group, Inc.
Industry
Eligibility
22 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

NCT04665154
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MAS825, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Tempe, Arizona • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

NCT02398188
View directory record Official record
Conditions
Central Abdominal Bulging
Interventions
LIPO-202, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery

NCT03241485
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 14, 2026, 5:34 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT04484818
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
115
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline for the Treatment of Smokeless Tobacco

NCT00813917
View directory record Official record
Conditions
Nicotine Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

NCT04473690
View directory record Official record
Conditions
Covid19
Interventions
Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 14, 2026, 5:34 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982
View directory record Official record
Conditions
Spinal Muscular Atrophy (SMA)
Interventions
ARGX-119 IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Terminated Not applicable Interventional

Efficacy of BFR Training Combined With Eccentric Exercise as Assessed by SWE in Subjects With Chronic AT

NCT03264326
View directory record Official record
Conditions
Achilles Tendinopathy
Interventions
Blood Flow Restriction Training, Sham Blood Flow Restriction Training, Eccentric Exercise
Other
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia

NCT00803023
View directory record Official record
Conditions
Fibromyalgia
Interventions
Sodium Oxybate, Sodium Oxybate & 6 Tablets, Sodium Oxybate & 8 Tablets, Sodium Oxybate Oral Solution (6 grams)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
32
States / cities
Phoenix, Arizona • Anaheim, California • Fair Oaks, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 14, 2026, 5:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

NCT01890889
View directory record Official record
Conditions
Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions
Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

NCT05772520
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TLL018 tablets
Drug
Lead sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Active, not recruiting Phase 2 Interventional

Effects of Simvastatin on Uterine Leiomyoma Size

NCT03400826
View directory record Official record
Conditions
Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Interventions
Simvastatin 40mg, Placebo 40 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

The Effects of Naltrexone on Active Crohn's Disease

NCT00663117
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
Naltrexone-HCl, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 14, 2026, 5:34 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds

NCT06792474
View directory record Official record
Conditions
Spinal Disease, Anesthesia, Post Operative Pain
Interventions
Lidocaine in Saline, Normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 14, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Long-term COVID and Rehabilitation

NCT05373043
View directory record Official record
Conditions
Long-COVID
Interventions
Mitoquinone, Placebo
Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Terminated Phase 2Phase 3 Interventional

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

NCT06613685
View directory record Official record
Conditions
HIV-1-infection
Interventions
lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 4 Interventional Results available

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

NCT05548647
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 5:34 PM EDT
Completed Phase 2 Interventional

Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)

NCT00839176
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
RX-10100
Drug
Lead sponsor
Rexahn Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Denver, Colorado • Atlanta, Georgia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 14, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional Results available

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 14, 2026, 5:34 PM EDT
Recruiting Phase 1 Interventional

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

NCT03973268
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Major Depression
Interventions
Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions
Device · Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 5:34 PM EDT